Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology

07-05-2024 | Sarcoma

Genetic Predisposition to Sarcoma: What Should Clinicians Know?

Authors: Jennie Vagher, CGC, Casey J. Mehrhoff, DO, MS, Vaia Florou, MD, MS, Luke D. Maese, DO

Published in: Current Treatment Options in Oncology

Login to get access

Opinion statement

Pathogenic germline variants in the setting of several associated cancer predisposition syndromes (CPS) may lead to the development of sarcoma. We would consider testing for a CPS in patients with a strong family history of cancer, multiple primary malignancies, and/or pediatric/adolescent/young adult patients diagnosed with other malignancies strongly associated with CPS. When a CPS is diagnosed in a patient with sarcoma, additional treatment considerations and imaging options for those patients are required. This applies particularly to the use of radiation therapy, ionizing radiation with diagnostic imaging, and the use of alkylating chemotherapy. As data and guidelines are currently lacking for many of these scenarios, we have adopted a shared decision-making process with patients and their families. If the best chance for cure in a patient with CPS requires utilization of radiation therapy or alkylating chemotherapy, we discuss the risks with the patient but do not omit these modalities. However, if there are treatment options that yield equivalent survival rates, yet avoid these modalities, we elect for those options. Considering staging imaging and post-therapy evaluation for sarcoma recurrence, we avoid surveillance techniques that utilize ionizing radiation when possible but do not completely omit them when their use is indicated.
Literature
1.
• Vagher J, et al. Germline predisposition to soft tissue sarcoma. J Cancer Metastasis Treat. 2022;8:31. This reference is important as it has provided a detailed review of common soft tissue sarcomas related to cancer predisposition syndromes.
2.
3.
4.
•• Kumamoto T, et al. Medical guidelines for Li–Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol. 2021;26:2161–2178. This article is of major importance as it provides screening guidelines for LFS.
5.
6.
Li H, et al. Germline cancer predisposition variants in pediatric rhabdomyosarcoma: a report from the children’s oncology group. JNCI J Natl Cancer Inst. 2021;113(7):875–883.
7.
Fair D, et al. TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children’s Oncology Group report. Pediatr Blood Cancer. 2023;70(9): e30413.CrossRef
8.
Schultz KAP, et al. DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies. Clin Cancer Res. 2018;24(10):2251–61.PubMedPubMedCentralCrossRef
9.
Apellaniz-Ruiz M, McCluggage WG, Foulkes WD. DICER1-associated embryonal rhabdomyosarcoma and adenosarcoma of the gynecologic tract: pathology, molecular genetics, and indications for molecular testing. Genes Chromosomes Cancer. 2021;60(3):217–33.PubMedCrossRef
10.
11.
12.
Mussa A, et al. Cancer risk in Beckwith-Wiedemann syndrome: a systematic review and meta-analysis outlining a novel (epi)genotype specific histotype targeted screening protocol. J Pediatr. 2016;176:142–149 e1.
13.
Ducatman BS, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57(10):2006–21.
14.
Wong WW, et al. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42(2):351–60.PubMedCrossRef
15.
Anghileri M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer: Interdiscip Int J Am Cancer Soc. 2006;107(5):1065–1074.
16.
17.
Stucky CC, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878–85.PubMedCrossRef
18.
19.
20.
Gillani R, et al. Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. Am J Hum Genet. 2022;109(6):1026–37.PubMedPubMedCentralCrossRef
21.
Mirabello L, et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 2020;6(5):724–34.PubMedPubMedCentralCrossRef
22.
Diessner BJ, et al. Nearly half of TP53 germline variants predicted to be pathogenic in patients with osteosarcoma are de novo: a report from the Children’s Oncology Group. JCO Precis Oncol. 2020;4:1187–95.CrossRef
23.
24.
Wong FL, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA. 1997;278(15):1262–7.PubMedCrossRef
25.
Bougeard G, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33(21):2345–52.PubMedCrossRef
26.
Villani A, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12(6):559–67.PubMedCrossRef
27.
de Andrade KC, et al. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 2021;22(12):1787–98.PubMedPubMedCentralCrossRef
28.
Kleinerman RA, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272–9.PubMedCrossRef
29.
MacCarthy A, et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951–2004. Br J Cancer. 2013;108(12):2455–63.PubMedPubMedCentralCrossRef
30.
Bright CJ, et al. Risk of soft-tissue sarcoma among 69 460 five-year survivors of childhood cancer in Europe. JNCI J Natl Cancer Inst. 2018;110(6): 649–660.
31.
Kleinerman RA, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007;99(1):24–31.PubMedCrossRef
32.
33.
34.
Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma.” Am J Surg Pathol. 2011;35(4):599–607.PubMedCrossRef
35.
Fallen T, et al. Desmoid tumors–a characterization of patients seen at Mayo Clinic 1976–1999. Fam Cancer. 2006;5(2):191–4.PubMedCrossRef
36.
37.
Bourdeaut F, et al. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res. 2011;17(1):31–8.PubMedCrossRef
38.
39.
Schneppenheim R, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet. 2010;86(2):279–84.PubMedPubMedCentralCrossRef
40.
Nemes K, Bens S, Bourdeaut F. Rhabdoid tumor predisposition syndrome, 2017 Dec 7. GeneReviews®[Internet]. Seattle: University of Washington; 1993.
41.
Hirota S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.PubMedCrossRef
42.
Ponti G, et al. Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep. 2010;23(2):437–44.PubMed
43.
Postow MA, Robson ME. Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. Clin Sarcoma Res. 2012;2(1):16.PubMedPubMedCentralCrossRef
44.
Chompret A, et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology. 2004;126(1):318–21.PubMedCrossRef
45.
Janeway KA, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011;108(1):314–8.PubMedCrossRef
46.
Miettinen M, et al. Succinate dehydrogenase deficient gists–a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric gists with predilection to young age. Am J Surg Pathol. 2011;35(11):1712.PubMedPubMedCentralCrossRef
47.
Zoller ME, et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 1997;79(11):2125–31.PubMedCrossRef
48.
49.
Parry DM, et al. Clinical findings in families with chordoma with and without T gene duplications and in patients with sporadic chordoma reported to the surveillance, epidemiology, and end results program. J Neurosurg. 2020;134(5):1399–408.PubMedPubMedCentralCrossRef
50.
Kelley M, et al. Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma. Hum Genet. 2014;133(10):1289.PubMedPubMedCentralCrossRef
51.
Pillay N, et al. A common single-nucleotide variant in T is strongly associated with chordoma. Nat Genet. 2012;44(11):1185–7.PubMedCrossRef
52.
53.
54.
El Abiad JM, et al. Natural history of Ollier disease and Maffucci syndrome: patient survey and review of clinical literature. Am J Med Genet A. 2020;182(5):1093–103.PubMedPubMedCentralCrossRef
55.
56.
West JG, et al. BRCA mutations and the risk of angiosarcoma after breast cancer treatment. Clin Breast Cancer. 2008;8(6):533–7.PubMedCrossRef
57.
Kadouri L, et al. Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations. Breast Cancer Res Treat. 2013;140(1):207–11.PubMedCrossRef
58.
59.
Calvete O, et al. A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families. Nat Commun. 2015;6:8383.PubMedCrossRef
60.
Anderson WJ, Doyle LA. Updates from the 2020 World Health Organization classification of soft tissue and bone tumours. Histopathology. 2021;78(5):644–57.PubMedCrossRef
61.
62.
Hampel H, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70–87.PubMedCrossRef
63.
•• Waespe N, et al. Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer–a national cohort study. Eur J Cancer. 2021;145:71–80. This article is of major importance as it outlines the risks for secondary primary malignancies in pediatric patients in relation to their cancer predisposition syndrome.
64.
Stiller CA, et al. Subsequent cancers within 5 years from initial diagnosis of childhood cancer. Patterns and risks in the population of Great Britain. Pediatr Blood Cancer 2023;70(5): e30258.
65.
Eulo V, et al. Secondary sarcomas: biology, presentation, and clinical care. Am Soc Clin Oncol Educ Book. 2020;40:463–74.CrossRef
66.
•• Hendrickson PG, et al. Radiation therapy and secondary malignancy in Li‐Fraumeni syndrome: a hereditary cancer registry study. Cancer Med. 2020;9(21): 7954–7963. This article is of major importance as it proved radiation therapy does not significantly increase the risk for second primary malignancies induced by RT in patients with LFS.
67.
68.
Kasper E, et al. Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations. Eur J Cancer. 2018;101:254–62.PubMedCrossRef
69.
• Clarke JE, et al. Radiologic screening and surveillance in hereditary cancers. Eur J Radiol Open. 2022;9: 100422. This article is of importance as it shows that imaging surveillance with whole body MRI is beneficial in patients with cancer predisposition syndromes.
70.
Reid JR. Ionizing radiation use and cancer predisposition syndromes in children. J Am Coll Radiol. 2018;15(9):1238–9.PubMedCrossRef
Metadata
Title
Genetic Predisposition to Sarcoma: What Should Clinicians Know?
Authors
Jennie Vagher, CGC
Casey J. Mehrhoff, DO, MS
Vaia Florou, MD, MS
Luke D. Maese, DO
Publication date
07-05-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-024-01192-6
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits